Developer docs
API playgroundTry for free, no card

Search company profiles

Orexo US, Inc.

Full company profile

uuid005jg5m

Namestring
Orexo US, Inc.
Legal namestring
Orexo US, Inc.
Websiteurl
us.orexo.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Orexo US, Inc. is the wholly-owned United States subsidiary of Orexo AB (publ), a Swedish pharmaceutical company publicly traded on Nasdaq Stockholm (ticker: ORX). The US entity is headquartered in Parsippany, New Jersey with approximately 25 employees, and its stated mission is to bring innovative treatment solutions to US patients with severe diseases and life-threatening conditions requiring rescue medications. The subsidiary operates as the US commercial and corporate-presence arm of the parent group, with no independent R&D footprint disclosed.

The company's core technology is AmorphOX®, a proprietary drug delivery platform developed and owned by parent Orexo AB (publ) that improves the bioavailability and chemical stability of both large and small molecule APIs. AmorphOX® is positioned as a formulation science platform enabling new routes of administration, manufacturing processes, and distribution approaches, and is described as a differentiator that the US entity inherits rather than develops independently. No specific commercial product lines, branded assets, or pipeline candidates attributable to the US subsidiary are disclosed in the source material.

The business model is that of a strategic operating subsidiary executing US-market commercialization, medical affairs, and market access activities on behalf of the parent group's portfolio. The US leadership team comprises a Chief Medical Officer (Edward Kim, MD, since October 2022), a Senior Vice President of Product and Portfolio Strategy (Lisa M. Moore, since May 2024, with prior opioid rescue commercial leadership at Emergent BioSolutions), and a Senior Vice President of Market Access & Government Affairs (Rich Murphy, since August 2013, with 30+ years at Bayer, Merck, and other multinationals). No pricing model, revenue mechanics, distribution channels, payer mix, or customer concentration data is publicly disclosed, and no M&A, partnership, or funding activity specific to the US entity is on record.

Short descriptiontext

Orexo US, Inc. is the wholly-owned US subsidiary of Sweden-based Orexo AB (publ), operating a 25-person commercial, medical affairs, and market access organization in Parsippany, NJ to bring the parent's AmorphOX®-based severe-disease and rescue medications to US patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery technology, pharmaceutical development, rescue medications, severe disease treatments, bioavailability enhancement
Industry1 code
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
Cost components5 values
Personnel, Marketing or Sales, Operations, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Orexo US, Inc. is the U.S. subsidiary of Orexo AB (publ), a Swedish pharmaceutical company. The company develops and commercializes pharmaceutical products based on its proprietary AmorphOX® drug delivery technology, focused on treatments for severe diseases and life-saving rescue medications. Operating from Parsippany, New Jersey, the unit leads U.S. market entry, product strategy, and market access for Orexo's specialty pharmaceutical portfolio.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Orexo US, Inc. is a pharmaceutical company that operates as the US subsidiary of Orexo AB (publ). The company's core offering centers on its proprietary AmorphOX® drug delivery technology, which is designed to improve bioavailability and stability for pharmaceutical applications. The company focuses on developing treatments for severe diseases and life-saving rescue medications.

Product and service1 record
1AmorphOX® Drug Delivery Technology Platform
CategoryPharmaceutical Drug Delivery Technology
Description

A proprietary, powder-based drug delivery technology platform used to develop pharmaceutical products with improved stability, solubility, and bioavailability. It underpins Orexo's pipeline of treatments for severe diseases and life-saving rescue medications marketed through the U.S. subsidiary.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Opiant Pharmaceuticals
TypeDirect peer
Description

Opiant Pharmaceuticals (now part of Indivior) developed opioid overdose rescue therapeutics including nasal naloxone. It is a direct peer in the opioid overdose rescue / substance use disorder category that Orexo US is targeting.

TypeBroad incumbent
Description

Hikma Pharmaceuticals is a multinational specialty and generic pharma with a substantial US presence in injectable, respiratory, and CNS categories. It is a broad incumbent comparable to Orexo US in the US specialty pharma space.

TypeDirect peer
Description

Collegium Pharmaceutical is a US specialty pharma focused on responsible pain management and CNS therapeutics. It is a comparable peer in the US severe-disease and CNS specialty pharma space Orexo US is targeting.

TypeEmerging player
Description

Catalent is a global drug delivery and development services / CDMO with proprietary formulation technologies across multiple dosage forms. It is a comparable peer to Orexo's AmorphOX® drug delivery platform, though it operates primarily as a service provider rather than a product company.

TypeDirect peer
Description

Alkermes is a specialty pharma with a proprietary drug delivery technology platform (e.g., NanoCrystal®, LinkeRx®) and a CNS-focused portfolio. It is the most directly comparable peer to Orexo's AmorphOX®-based, CNS/rescue-focused specialty pharma model.

TypeDirect peer
Description

Emergent BioSolutions is a direct competitor in the US opioid overdose rescue category through its NARCAN® (naloxone) nasal spray franchise. It is the most directly comparable peer given Orexo US's apparent focus on opioid overdose rescue and severe-disease rescue medications, and the fact that key US leader Lisa Moore came directly from Emergent's SUD/opioid franchise.

TypeBroad incumbent
Description

Pfizer is a large multinational pharma that acquired Biohaven (former employer of Orexo US's CMO) and operates broadly in CNS and specialty pharma. It is a broad incumbent in the severe-disease and CNS spaces Orexo US is targeting.

TypeEmerging player
Description

Biohaven Pharmaceuticals (now part of Pfizer) developed migraine and CNS therapeutics and was the previous employer of Orexo US's CMO Edward Kim. It is a relevant peer in the CNS specialty pharma space where Orexo US's pipeline appears focused.

TypeDirect peer
Description

Indivior is a global specialty pharma focused on substance use disorder and addiction treatments. Its marketed SUBLOCADE® and other opioid-related products make it a direct peer in the SUD/rescue medication space Orexo US is pursuing.

TypeEmerging player
Description

Adapt Pharma (acquired by Emergent BioSolutions) was the original US marketer of NARCAN® nasal spray for opioid overdose. It is a relevant peer in the opioid overdose rescue category that Orexo US is positioned to compete in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orexo US, Inc.

Specialty Pharmaceuticalsus.orexo.com

Orexo US, Inc. is the wholly-owned US subsidiary of Sweden-based Orexo AB (publ), operating a 25-person commercial, medical affairs, and market access organization in Parsippany, NJ to bring the parent's AmorphOX®-based severe-disease and rescue medications to US patients.

What Orexo US, Inc. does

Orexo US, Inc. is the wholly-owned United States subsidiary of Orexo AB (publ), a Swedish pharmaceutical company publicly traded on Nasdaq Stockholm (ticker: ORX). The US entity is headquartered in Parsippany, New Jersey with approximately 25 employees, and its stated mission is to bring innovative treatment solutions to US patients with severe diseases and life-threatening conditions requiring rescue medications. The subsidiary operates as the US commercial and corporate-presence arm of the parent group, with no independent R&D footprint disclosed.

The company's core technology is AmorphOX®, a proprietary drug delivery platform developed and owned by parent Orexo AB (publ) that improves the bioavailability and chemical stability of both large and small molecule APIs. AmorphOX® is positioned as a formulation science platform enabling new routes of administration, manufacturing processes, and distribution approaches, and is described as a differentiator that the US entity inherits rather than develops independently. No specific commercial product lines, branded assets, or pipeline candidates attributable to the US subsidiary are disclosed in the source material.

The business model is that of a strategic operating subsidiary executing US-market commercialization, medical affairs, and market access activities on behalf of the parent group's portfolio. The US leadership team comprises a Chief Medical Officer (Edward Kim, MD, since October 2022), a Senior Vice President of Product and Portfolio Strategy (Lisa M. Moore, since May 2024, with prior opioid rescue commercial leadership at Emergent BioSolutions), and a Senior Vice President of Market Access & Government Affairs (Rich Murphy, since August 2013, with 30+ years at Bayer, Merck, and other multinationals). No pricing model, revenue mechanics, distribution channels, payer mix, or customer concentration data is publicly disclosed, and no M&A, partnership, or funding activity specific to the US entity is on record.

Orexo US, Inc. firmographics

Firmographics
Name
Orexo US, Inc.
Legal name
Orexo US, Inc.
Website
https://us.orexo.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Orexo US, Inc. is the wholly-owned US subsidiary of Sweden-based Orexo AB (publ), operating a 25-person commercial, medical affairs, and market access organization in Parsippany, NJ to bring the parent's AmorphOX®-based severe-disease and rescue medications to US patients.
Ownership category
akta.pro rank

Orexo US, Inc. industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Drug delivery technology
  • Pharmaceutical development
  • Rescue medications
  • Severe disease treatments
  • Bioavailability enhancement

Where Orexo US, Inc. is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Orexo US, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Orexo US, Inc. product offering

Product offering

Core offering

Orexo US, Inc. is the U.S. subsidiary of Orexo AB (publ), a Swedish pharmaceutical company. The company develops and commercializes pharmaceutical products based on its proprietary AmorphOX® drug delivery technology, focused on treatments for severe diseases and life-saving rescue medications. Operating from Parsippany, New Jersey, the unit leads U.S. market entry, product strategy, and market access for Orexo's specialty pharmaceutical portfolio.

Product overview

Orexo US, Inc. is a pharmaceutical company that operates as the US subsidiary of Orexo AB (publ). The company's core offering centers on its proprietary AmorphOX® drug delivery technology, which is designed to improve bioavailability and stability for pharmaceutical applications. The company focuses on developing treatments for severe diseases and life-saving rescue medications.

Differentiator

Problem solved

Functional benefit

Products and services

  • AmorphOX® Drug Delivery Technology Platform A proprietary, powder-based drug delivery technology platform used to develop pharmaceutical products with improved stability, solubility, and bioavailability. It underpins Orexo's pipeline of treatments for severe diseases and life-saving rescue medications marketed through the U.S. subsidiary.

Companies that use Orexo US, Inc.

Customer profile

Segments1 record

Ideal customer profiles1 record

Orexo US, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Orexo US, Inc. partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Orexo US, Inc. competitors and assessment

Company assessment

Direct peers

  • Opiant Pharmaceuticals: Opiant Pharmaceuticals (now part of Indivior) developed opioid overdose rescue therapeutics including nasal naloxone. It is a direct peer in the opioid overdose rescue / substance use disorder category that Orexo US is targeting.
  • Collegium Pharmaceutical: Collegium Pharmaceutical is a US specialty pharma focused on responsible pain management and CNS therapeutics. It is a comparable peer in the US severe-disease and CNS specialty pharma space Orexo US is targeting.
  • Alkermes: Alkermes is a specialty pharma with a proprietary drug delivery technology platform (e.g., NanoCrystal®, LinkeRx®) and a CNS-focused portfolio. It is the most directly comparable peer to Orexo's AmorphOX®-based, CNS/rescue-focused specialty pharma model.
  • Emergent BioSolutions: Emergent BioSolutions is a direct competitor in the US opioid overdose rescue category through its NARCAN® (naloxone) nasal spray franchise. It is the most directly comparable peer given Orexo US's apparent focus on opioid overdose rescue and severe-disease rescue medications, and the fact that key US leader Lisa Moore came directly from Emergent's SUD/opioid franchise.
  • Indivior: Indivior is a global specialty pharma focused on substance use disorder and addiction treatments. Its marketed SUBLOCADE® and other opioid-related products make it a direct peer in the SUD/rescue medication space Orexo US is pursuing.

Broad incumbents

  • Hikma Pharmaceuticals: Hikma Pharmaceuticals is a multinational specialty and generic pharma with a substantial US presence in injectable, respiratory, and CNS categories. It is a broad incumbent comparable to Orexo US in the US specialty pharma space.
  • Pfizer (post-Biohaven): Pfizer is a large multinational pharma that acquired Biohaven (former employer of Orexo US's CMO) and operates broadly in CNS and specialty pharma. It is a broad incumbent in the severe-disease and CNS spaces Orexo US is targeting.

Emerging players

  • Catalent: Catalent is a global drug delivery and development services / CDMO with proprietary formulation technologies across multiple dosage forms. It is a comparable peer to Orexo's AmorphOX® drug delivery platform, though it operates primarily as a service provider rather than a product company.
  • Biohaven Pharmaceuticals: Biohaven Pharmaceuticals (now part of Pfizer) developed migraine and CNS therapeutics and was the previous employer of Orexo US's CMO Edward Kim. It is a relevant peer in the CNS specialty pharma space where Orexo US's pipeline appears focused.
  • Adapt Pharma (now part of Emergent): Adapt Pharma (acquired by Emergent BioSolutions) was the original US marketer of NARCAN® nasal spray for opioid overdose. It is a relevant peer in the opioid overdose rescue category that Orexo US is positioned to compete in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Orexo US, Inc. social profiles

Digital presence

Orexo US, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orexo US, Inc. leadership team

Management profile

Number of profiles

Profiles3 records

Orexo US, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orexo US, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orexo US, Inc.

What does Orexo US, Inc. do?

Orexo US, Inc. is the U.S. subsidiary of Orexo AB (publ), a Swedish pharmaceutical company. The company develops and commercializes pharmaceutical products based on its proprietary AmorphOX® drug delivery technology, focused on treatments for severe diseases and life-saving rescue medications. Operating from Parsippany, New Jersey, the unit leads U.S. market entry, product strategy, and market access for Orexo's specialty pharmaceutical portfolio.

Is Orexo US, Inc. a public or private company?

Orexo US, Inc. is a private company. It is classified as corporate owned and is currently operating.

When was Orexo US, Inc. founded?

Orexo US, Inc. was founded in -1. It employs 11 to 50 people.

Where is Orexo US, Inc. based?

Orexo US, Inc. is headquartered in Parsippany, United States, in the North America region.

Who are Orexo US, Inc.'s main competitors?

Direct peers on record are Opiant Pharmaceuticals, Collegium Pharmaceutical, Alkermes, Emergent BioSolutions and Indivior. Broad incumbents are Hikma Pharmaceuticals and Pfizer (post-Biohaven). Emerging players are Catalent, Biohaven Pharmaceuticals and Adapt Pharma (now part of Emergent).

Does Orexo US, Inc. have an API?

No public API is recorded for Orexo US, Inc..

What industry is Orexo US, Inc. in?

Orexo US, Inc.'s product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals